CF
RAPP

Corebridge Financial’s Rapport Therapeutics RAPP Stock Holding History

Corebridge Financial’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,271
Closed -$83K – 2931
2025
Q1 		$83K Buy
8,271
+3,653
+79% +$47.4K ﹤0.01% 2535
2024
Q4 		$81.9K Sell
4,618
-349
-7% -$7.73K ﹤0.01% 2644
2024
Q3 		$102K Buy
+4,967
New +$107K ﹤0.01% 2612

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Corebridge Financial's RAPP Position: Q2 2025 in Review

Corebridge Financial sold out of Rapport Therapeutics (RAPP) in Q2 2025, closing a stake of 8,271 shares — an estimated $83K sold.

Corebridge Financial first reported a position in RAPP in Q3 2024 and held it in 3 quarters. The position peaked at $102K in Q3 2024. 82 funds tracked by Wall St. Rank hold RAPP as of Q2 2025.

  • Corebridge Financial reported no remaining Rapport Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 8,271 Rapport Therapeutics shares in Q2 2025, an estimated $83K.
  • Corebridge Financial first reported a position in Rapport Therapeutics in Q3 2024 and held it in 3 quarters.
  • Corebridge Financial's Rapport Therapeutics position peaked at $102K in Q3 2024.
  • 82 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.